Journal
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
Volume 21, Issue 9, Pages 2318-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2022.06.007
Keywords
Cirrhosis; Portal Pressure; Nonselective b-Blocker; Variceal Bleeding
Categories
Ask authors/readers for more resources
In this study, it was found that carvedilol is more effective than propranolol in the secondary prophylaxis of variceal bleeding, as it induces more significant reductions in hepatic venous pressure gradient (HVPG) and is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation.
BACKGROUND & AIMS: Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than con-ventional nonselective 0-blockers (ie, propranolol). Limited data exist on the efficacy of car-vedilol in secondary prophylaxis of variceal bleeding. METHODS: Patients undergoing paired HVPG measurements for guiding secondary prophylaxis with either carvedilol or propranolol were included in this retrospective analysis. All patients also un-derwent band ligation. Changes in HVPG and systemic hemodynamics were compared between the 2 groups. Long-term follow-up data on rebleeding, acute kidney injury, nonbleeding decompensation, and liver-related death were analyzed applying competing risk regression. RESULTS: Eighty-seven patients (carvedilol/propranolol, n [ 45/42) were included in our study. The median baseline HVPG was 21 mm Hg (interquartile range, 18-24 mm Hg), and 39.1%/48.3%/ 12.6% had Child-Turcotte-Pugh A/B/C cirrhosis, respectively. Upon nonselective 0-blocker initiation, HVPG decreased more strongly in carvedilol users (median relative decrease,-20% [interquartile range:-29% to-10%] vs-11% [-22% to-5%] for propranolol; P = .027), who also achieved chronic HVPG response more often (53.3% vs 28.6%; P = .034). Cumulative incidences for rebleeding (Gray test, P = .027) and liver-related death (P = .036) were signifi- cantly lower in patients taking carvedilol compared with propranolol. Notably, ascites development/worsening also was observed less commonly in carvedilol patients (P = .012). Meanwhile, acute kidney injury rates did not differ between the 2 groups (P = .255). Stratifying patients by HVPG response status yielded similar results. The prognostic value of carvedilol intake was confirmed in competing risk regression models. CONCLUSIONS: Carvedilol induces more marked reductions in HVPG than propranolol in secondary prophylaxis of variceal bleeding, and thus is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available